Wasdell Group launches serialisation service
![](/46/pdcnewsitem/07/38/72/carton-serialisation.jpg)
Company will offer compliant products to all markets, including Europe and the US.
The Wasdell Group, a leading outsourcing partner to companies within the pharmaceutical, medical device and clinical trials industries, has launched its serialisation service ahead of the EU FMD and US DSCSA implementation deadlines.
Following a £2.8 million investment into serialisation capabilities in 2016, the company will offer compliant products to all markets, including Europe and the US, from its sites in Newcastle and Swindon.
Wasdell’s new facility in Ireland, due to open January 2019, will also offer serialisation for all products.
Daniel Tedham, managing director of Wasdell Manufacturing said: ”Wasdell operate on a global scale making the ability to comply with regulations of various markets essential, so we made the choice to invest in our serialisation capabilities very early on.
”As a CMO we handle a huge variety of products that all have specific needs, as well as a customer base of over 250 unique customers who also have their own requirements. It was important that our solution meant we could remain flexible enough to meet these criteria, hence our proactive approach.
”Implementing a solution across multiple lines that need to supply to numerous markets is a challenging process that many companies have underestimated. We wanted to ensure we were ready well ahead of schedule to guarantee that we could effectively support current and future clients with compliance with the EU FMD, US DSCSA and other market regulations.”
As part of its serialisation service, Wasdell will also be able to offer three tier aggregation from carton to pallet to ensure compliance with future changes to regulations.
”Equipping our lines with aggregation capabilities means we are ready to continue supplying products to the US following the 2023 deadline for three-tier parent-child relationships between barcodes and that we can deal with future amends to regulations in other markets.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance